Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Shares Outstanding (Weighted Average) (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $6.1 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Shares Outstanding (Weighted Average) fell 83.37% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Sep 2019, down 83.37%, and an annual FY2018 reading of $37.0 million, up 35.0% over the prior year.
  • Shares Outstanding (Weighted Average) was $6.1 million for Q3 2019 at Larimar Therapeutics, roughly flat from $6.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $37.3 million in Q1 2019 and bottomed at $6.1 million in Q2 2019.
  • Average Shares Outstanding (Weighted Average) over 5 years is $26.5 million, with a median of $27.3 million recorded in 2016.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 3411.87% in 2015, then crashed 83.37% in 2019.
  • Year by year, Shares Outstanding (Weighted Average) stood at $26.8 million in 2015, then grew by 2.03% to $27.3 million in 2016, then rose by 0.5% to $27.4 million in 2017, then surged by 35.0% to $37.0 million in 2018, then crashed by 83.55% to $6.1 million in 2019.
  • Business Quant data shows Shares Outstanding (Weighted Average) for LRMR at $6.1 million in Q3 2019, $6.1 million in Q2 2019, and $37.3 million in Q1 2019.